Position
Mullaney, Keating & Wright, Inc. in AbbVie Inc.
Back to the book · All holders of ABBV
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$21.2K$228.49 → $217.49
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q2 2024 | 1.98K | $339.6K | — | — | — | 0.3% |
| Q3 2024 | 1.98K | $391K | $197.48 | $51.4K | $0 | 0.3% |
| Q4 2024 | 1.95K | $346.5K | $177.70 | −$38.6K | −$5.92K | 0.2% |
| Q1 2025 | 1.93K | $404.4K | $209.52 | $61.4K | −$3.55K | 0.3% |
| Q2 2025 | 1.93K | $358.2K | $185.62 | −$46.1K | $0 | 0.2% |
| Q3 2025 | 1.93K | $446.9K | $231.54 | $88.6K | −$0 | 0.2% |
| Q4 2025 | 1.93K | $441K | $228.49 | −$5.89K | $0 | 0.2% |
| Q1 2026 | 1.93K | $419.8K | $217.49 | −$21.2K | $0 | 0.2% |